已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

医学 去甲柔比星 三氧化二砷 内科学 急性早幼粒细胞白血病 养生 化疗 胃肠病学 化疗方案 阿糖胞苷 维甲酸 砷 生物化学 基因 有机化学 化学
作者
Alan K. Burnett,Nigel H. Russell,Robert K. Hills,David Bowen,Jonathan Kell,Steven Knapper,Yvonne G Morgan,Jennie Lok,Angela Grech,Gail Jones,Asim Khwaja,Lone S. Friis,Mary Frances McMullin,Ann Hunter,Richard E. Clark,David Grimwade
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (13): 1295-1305 被引量:536
标识
DOI:10.1016/s1470-2045(15)00193-x
摘要

Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute myeloid leukaemia characterised by the presence of the PML-RARA fusion transcript. The present standard of care, chemotherapy and all-trans retinoic acid (ATRA), results in a high proportion of patients being cured. In this study, we compare a chemotherapy-free ATRA and arsenic trioxide treatment regimen with the standard chemotherapy-based regimen (ATRA and idarubicin) in both high-risk and low-risk patients with acute promyelocytic leukaemia.In the randomised, controlled, multicentre, AML17 trial, eligible patients (aged ≥16 years) with acute promyelocytic leukaemia, confirmed by the presence of the PML-RARA transcript and without significant cardiac or pulmonary comorbidities or active malignancy, and who were not pregnant or breastfeeding, were enrolled from 81 UK hospitals and randomised 1:1 to receive treatment with ATRA and arsenic trioxide or ATRA and idarubicin. ATRA was given to participants in both groups in a daily divided oral dose of 45 mg/m(2) until remission, or until day 60, and then in a 2 weeks on-2 weeks off schedule. In the ATRA and idarubicin group, idarubicin was given intravenously at 12 mg/m(2) on days 2, 4, 6, and 8 of course 1, and then at 5 mg/m(2) on days 1-4 of course 2; mitoxantrone at 10 mg/m(2) on days 1-4 of course 3, and idarubicin at 12 mg/m(2) on day 1 of the final (fourth) course. In the ATRA and arsenic trioxide group, arsenic trioxide was given intravenously at 0·3 mg/kg on days 1-5 of each course, and at 0·25 mg/kg twice weekly in weeks 2-8 of course 1 and weeks 2-4 of courses 2-5. High-risk patients (those presenting with a white blood cell count >10 × 10(9) cells per L) could receive an initial dose of the immunoconjugate gemtuzumab ozogamicin (6 mg/m(2) intravenously). Neither maintenance treatment nor CNS prophylaxis was given to patients in either group. All patients were monitored by real-time quantitative PCR. Allocation was by central computer minimisation, stratified by age, performance status, and de-novo versus secondary disease. The primary endpoint was quality of life on the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 global health status. All analyses are by intention to treat. This trial is registered with the ISRCTN registry, number ISRCTN55675535.Between May 8, 2009, and Oct 3, 2013, 235 patients were enrolled and randomly assigned to ATRA and idarubicin (n=119) or ATRA and arsenic trioxide (n=116). Participants had a median age of 47 years (range 16-77; IQR 33-58) and included 57 high-risk patients. Quality of life did not differ significantly between the treatment groups (EORTC QLQ-C30 global functioning effect size 2·17 [95% CI -2·79 to 7·12; p=0·39]). Overall, 57 patients in the ATRA and idarubicin group and 40 patients in the ATRA and arsenic trioxide group reported grade 3-4 toxicities. After course 1 of treatment, grade 3-4 alopecia was reported in 23 (23%) of 98 patients in the ATRA and idarubicin group versus 5 (5%) of 95 in the ATRA and arsenic trioxide group, raised liver alanine transaminase in 11 (10%) of 108 versus 27 (25%) of 109, oral toxicity in 22 (19%) of 115 versus one (1%) of 109. After course 2 of treatment, grade 3-4 alopecia was reported in 25 (28%) of 89 patients in the ATRA and idarubicin group versus 2 (3%) of 77 in the ATRA and arsenic trioxide group; no other toxicities reached the 10% level. Patients in the ATRA and arsenic trioxide group had significantly less requirement for most aspects of supportive care than did those in the ATRA and idarubicin group.ATRA and arsenic trioxide is a feasible treatment in low-risk and high-risk patients with acute promyelocytic leukaemia, with a high cure rate and less relapse than, and survival not different to, ATRA and idarubicin, with a low incidence of liver toxicity. However, no improvement in quality of life was seen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
一锅炖不下完成签到,获得积分20
2秒前
xcgh给法就的求助进行了留言
2秒前
YBadada完成签到,获得积分10
3秒前
unik完成签到,获得积分10
3秒前
潘森爱科研完成签到,获得积分10
4秒前
Jane发布了新的文献求助10
4秒前
领导范儿的应助被LIUDAN采纳,获得10
7秒前
ralph_liu完成签到,获得积分10
7秒前
7秒前
cnspower的应助被JiuJiu采纳,获得30
8秒前
格物致知完成签到,获得积分10
8秒前
SciGPT的应助被hejiacheng采纳,获得50
9秒前
英俊的铭的应助被Rina采纳,获得10
9秒前
Owen的应助被Jane采纳,获得10
9秒前
Tori发布了新的文献求助50
9秒前
10秒前
某个不想做人的dio完成签到,获得积分10
11秒前
11秒前
shenxian82133发布了新的文献求助10
11秒前
12秒前
Maestro_S的应助被nuodei采纳,获得10
13秒前
是驼驼呀完成签到,获得积分10
13秒前
14秒前
Non发布了新的文献求助30
15秒前
16秒前
飘逸的苡发布了新的文献求助20
17秒前
17秒前
rebecca发布了新的文献求助10
17秒前
18秒前
影月cindy的应助被西西采纳,获得10
18秒前
19秒前
Waitcy发布了新的文献求助10
19秒前
crab发布了新的文献求助10
20秒前
Maestro_S的应助被小叶不吃香菜采纳,获得10
20秒前
随心晴发布了新的文献求助10
21秒前
李爱国的应助被石永怡采纳,获得10
22秒前
odd发布了新的文献求助10
23秒前
852的应助被舒书采纳,获得10
24秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194612
求助须知:如何正确求助?哪些是违规求助? 9580394
关于积分的说明 21870930
捐赠科研通 7794182
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484411